Among these strategies, targeting lysyl oxidase (LOX) activity that is frequently upregulated in diverse cancer types and responsible for catalyzing collagen crosslinking is emerging as a optimal one, which can reduce the stroma density and consequently enhance the outcome of anticancer treatment [320–326]. Here, LOX is linked to cancer.